China Biologic Products (CBPO) Misses Q2 EPS by 17c on Revenues of $111M

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/7/2026

1. MRVL
2. ZS
3. PENG
4. STZ
5. MSFT
6. NVDA
7. SPY
8. SKYD
9. IBM
10. CRWV

Go back to China Biologic Products (CBPO) Misses Q2 EPS by 17c on Revenues of $111M

China Biologic Reports Financial Results for the Second Quarter of 2020

August 17, 2020 4:30 PM EDT

BEIJING, Aug. 17, 2020 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its unaudited financial results for the second quarter of 2020.

Second Quarter 2020 Financial Highlights

Total sales in the second quarter of 2020 decreased by 14.9% in RMB terms and 18.1% in USD terms to $111.1 million from $135.7 million in the same quarter of 2019. Gross profit decreased by 16.0% to $76.4 million from $90.9 million in the same quarter of 2019. Gross margin increased to 68.8% from 67.0% in the same... More